All press releases | Innate Pharma

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

May 13, 2026
Innate Pharma reports full year 2025 financial results and business update

March 26, 2026
Innate Pharma reports Third Quarter 2025 business update and financial results

November 13, 2025
Innate Pharma Reports First Half 2025 Business Update And Financial Results

September 17, 2025
Innate Pharma highlights abstracts selected for ASCO 2025 annual meeting

May 19, 2025
Innate Pharma reports first quarter 2025 business update and financial results

May 13, 2025
Innate Pharma reports full year 2024 financial results and business update

March 27, 2025
Innate Pharma reports Third Quarter 2024 Business Update and Financial Results

November 13, 2024
Innate Pharma reports First Half 2024 Business Update and Financial Results

September 12, 2024
Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024

September 9, 2024

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers